Nicobrevin: withdrawn from UK market as risks outweigh benefits

01 April 2011

Giving up smoking is important for substantially improving long-term health. There are many effective treatments available to help the process of giving up smoking (see the MHRA 'stop smoking' webpage for more details). However, there are also some less effective and unsafe products available which may do more harm than good. One such product is an 'anti-smoking preparation' called Nicobrevin.

A review has concluded that Nicobrevin is ineffective as an anti-smoking treatment (and that none of its individual ingredients are effective for this purpose). In addition, several serious safety concerns associated with Nicobrevin and its ingredients were highlighted, showing that the risks of this product outweighed the benefits.

On the basis of these findings, the MHRA and Commission on Human Medicines concluded that Nicobrevin should be withdrawn from the UK market. Nicobrevin's licence was cancelled on 31st January 2011.

See also:

Article in May 2011 issue of Drug Safety Update (our monthly publication for health professionals on the safety of medicines and vaccines)

MHRA webpage on 'stop smoking' treatments

This report presents the evidence that was available when the regulatory decision was made, showing a ‘snapshot’ of the clinical landscape at the time. However, any advice in this report remains current unless it is superseded by a more recent report (where relevant, this is indicated).

Page last modified: 11 February 2016